2008 Best of the Rest in Urological Survey

References 

Hospital Lymph Node Counts and Survival After Radical Cystectomy
1. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 2003;169:946
   • Abstract
   • Full Text
   • Full-Text PDF (91 KB)
   • CrossRef

Five-Alpha-Reductase Inhibitors for Prostate Cancer Prevention
1. Kolata G. New take on a prostate drug and a new debate. New York Times, Sunday, June 15, 2008; pg 1, 23 http://query.nytimes.com/gst/fullpage.html?res=9E01E1DE123FF936A25755C0A96E9C8B63&scp=2&sq=prostate%20drug%20kolata&st=cse
2. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007;25:3076
   • CrossRef

Erectile Dysfunction as a Predictor of Cardiovascular Events and Death in Diabetic Patients With Angiographically Proven Asymptomatic Coronary Artery Disease: A Potential Protective Role for Statins and 5-Phosphodiesterase Inhibitors
1. Burnett AL. Erectile dysfunction. J Urol, suppl. 2006;175:S25
2. Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res. 2008;20:460
   • CrossRef
3. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996
   • CrossRef